At the end of July, a public comment period at the US Food and Drug Administration quietly closes. The proposal on the table would permanently remove semaglutide and tirzepatide, the active ingredients in drugs like Ozempic, Wegovy and Zepbound, from the list of substances that large compounding pharmacies are allowed to work with. In plain language: the last affordable route to GLP-1 drugs in the United States is being shut down.
Let’s be clear about what this article is not. Fatosphere does not recommend weight-loss drugs, and we are not going to argue that more people should be on them. Whether anyone takes a GLP-1 is their decision and nobody else’s business. But what is happening around these drugs right now is very much our business, because it shows, with unusual clarity, how body size is being turned into a class marker. GLP-1 access has become a sorting machine.
Three doors are closing at once
Door one: insurance. In Massachusetts, the state often used as a bellwether for US health policy, the major insurers Blue Cross Blue Shield and Point32Health stopped covering GLP-1s for weight reduction in early 2026, and the state employee plan (the Group Insurance Commission) and the Medicaid program (MassHealth) followed on July 1, as WBUR and the Boston Globe reported. Coverage for diabetes continues; it is the weight-management use that was cut. The people hit hardest are those who could never pay out of pocket.
Door two: the cheap workaround. When the brand-name drugs were in shortage, US law allowed compounding pharmacies to produce copies. At the peak in 2024, nearly one in three Americans on a GLP-1 got it from a compounder, often for a few hundred dollars a month instead of a list price above 1,000 dollars. The shortages are over, the legal basis is gone, and on April 30 the FDA proposed to close the remaining loophole for good, as Stanford Medicine reports. Warning letters have already gone out to dozens of telehealth sellers.
Door three: generics. The main patents don’t begin to expire until 2032 for semaglutide and 2036 for tirzepatide. There will be no cheap legal version for years.
To be fair: the safety concerns about compounded copies are real. Stanford Medicine clinicians describe untested chemical variants, dosing errors from multidose vials and inaccurate labels. Poison control calls related to injected weight-loss drugs have risen more than fifteenfold since 2019. Nobody should have to inject a mislabeled imitation product. But that is exactly the point: poor patients were pushed toward the risky version because the safe version was priced like a luxury good, and now the risky version disappears while the luxury pricing stays.
One door cracks open, briefly
There is one exception, and its shape proves the rule. On July 1 the US federal government started a temporary pilot: Medicare Part D members who meet strict criteria (a BMI of 35, or 27 with a condition such as heart disease, prediabetes or hypertension) can get Wegovy, Zepbound or the oral versions for a 50-dollar monthly copay. It runs only through the end of 2027, covers only prescriptions for weight management, and reaches an estimated 3.8 million people, a sliver of the GLP-1 market. So while private insurers in Massachusetts pull their coverage, a federal program cracks a narrow, time-limited window open for older and disabled Americans. The lesson is not that access is finally arriving. It is that access has turned into a lottery: which program you happen to be in, for how long, under which conditions. Everyone outside the lucky slice pays the list price or goes without.
The moral double-bind
Here is where it stops being a health-policy story and becomes a stigma story. Recent research found that GLP-1 users are judged as less moral because they supposedly didn’t “earn” their weight loss, and a 2026 survey found 43 percent of users hide the medication when dating. The old lie about fatness was that it proves laziness. The new lie is that thinness only counts if you suffered for it.
Put the two together and you get a perfect trap for fat people with low incomes. Society tells them their body is a personal failure. The pharmaceutical market prices the officially sanctioned exit at over 1,000 dollars a month. Insurers withdraw. The FDA closes the discount door. And whoever somehow still manages to take the drug is told they cheated.
You lose if you are fat. You lose if you can’t afford the drug. You lose if you take it. The only people who win are those wealthy enough to buy thinness quietly and never talk about it.
Thinness as a luxury good
None of this is new in kind, only in degree. Thinness has signaled wealth for decades, through gyms, personal trainers, food quality and free time. But a monthly subscription with a four-digit list price makes the logic explicit: the body type that protects you from discrimination in job interviews, at the doctor’s office and on dating apps is now literally a product with a price tag most people can’t pay.
That should worry everyone, including people who have no interest in these drugs. Because when thinness becomes purchasable, fatness reads even more strongly as poverty, and the stigma that fat people already face hardens into open class contempt.
What we actually demand
The fat-acceptance answer to this mess is not “GLP-1s for everyone.” It is the reminder that the entire arrangement rests on one assumption nobody is forced to accept: that a fat body is a problem requiring an expensive solution. Dignity is not something you should have to buy in monthly installments. GLP-1 access, like all healthcare, must not depend on income for people who want and need these drugs. And the right to live in a fat body without being treated as a walking failure must not depend on whether you can afford the alternative.
The FDA’s comment window closes at the end of July. The stigma stays open around the clock, and it doesn’t take comments.